Recent blog

Discussing DefiniGEN's iPSC-derived MASLD model with Head of R&D, Nikolaos Nikolaou

Latest resource

Developing iPSC-Derived Liver Systems for MASLD Modeling and Therapy Screening

Opti-HEP: iPSC-derived Human Hepatocytes

Physiologically relevant liver disease models that can be generated at scale for disease modeling, assay development and screening applications.

platform_1200x800
toxicology-screening_1200x800_v4

Disease Modeling

DefiniGEN's platform technology enables the generation of predictive and phenotypically relevant iPSC-derived human disease models for a wide range of metabolic and liver diseases which can be produced at scale.

Profiling Molecules

Combine our expertise at generating iPSC-derived hepatocyte disease models with our wide panel of bespoke bioassays. We work as partners with your team to design and implement in-house screening of small molecules and advanced genetic therapies, so you can advance your program at speed.

efficacy-screening_1200x800_v3
disease-modeling_1200x800_v3

Donor Variance Panel

DefiniGEN has a large panel of iPSC lines allowing us to offer all our disease models and cell-based bioassays in donors ranging in gender, age and ethnicity.  Researchers use our donor panels to further screen their lead candidates and potentially inform the stratification of a successful clinical trial.

Specialist CRO focused on delivering liver and metabolic disease models

Highly Predictive

Opti-HEPs successfully recapitulate key aspects of disease pathophysiology across a wide-range of conditions that affect different aspects of liver function

Scalable

DefiniGEN’s proprietary differentiation protocol permits large-scale generation of hepatocyte-like cells with field leading purity and functionality

Optimized Bioassay Development

Optimized bioassays that can accurately evaluate compound potency, efficacy and delivery

Scientific expertise

definigen-logo-background-overlay

Advance your scientific discoveries with our tailored disease modeling products and services